Disruptive Pharma AB (OSTO:DPHA) Piotroski F-Score: N/A (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:DPHA Disruptive Pharma AB OSTO:DPHA
4 GF Score
Price kr1.21
View Full Analysis

What is Disruptive Pharma AB Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Disruptive Pharma AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Disruptive Pharma AB's Piotroski F-Score or its related term are showing as below:

Disruptive Pharma AB  (OSTO:DPHA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Disruptive Pharma AB Piotroski F-Score Related Terms


Disruptive Pharma AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Disruptive Pharma AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Disruptive Pharma AB Piotroski F-Score Chart

Disruptive Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 2.00 2.00 2.00

Disruptive Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 3.00 4.00

OSTO:DPHA vs : Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Disruptive Pharma AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Disruptive Pharma AB Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Disruptive Pharma AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Disruptive Pharma AB's Piotroski F-Score falls into.


OSTO:DPHA
4GF Score
Disruptive Pharma AB OSTO:DPHA
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -26.085 + -16.33 + -6.351 + -4.364 = kr-53.13 Mil.
Cash Flow from Operations was -30.762 + -18.649 + -8.896 + -6.977 = kr-65.28 Mil.
Revenue was 0 + 0 + 0 + 0 = kr0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = kr0.00 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(101.868 + 70.877 + 54.143 + 45 + 39.753) / 5 = kr62.3282 Mil.
Total Assets at the begining of this year (Jun25) was kr101.87 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.
Total Current Assets was kr39.75 Mil.
Total Current Liabilities was kr5.69 Mil.
Net Income was -31.727 + -25.958 + -34.215 + -32.221 = kr-124.12 Mil.

Revenue was 0 + 0 + 0 + 0 = kr0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = kr0.00 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(93.038 + 75.561 + 55.741 + 72.049 + 101.868) / 5 = kr79.6514 Mil.
Total Assets at the begining of last year (Jun24) was kr93.04 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.
Total Current Assets was kr101.87 Mil.
Total Current Liabilities was kr21.31 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Disruptive Pharma AB's current Net Income (TTM) was -53.13. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Disruptive Pharma AB's current Cash Flow from Operations (TTM) was -65.28. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=-53.13/101.868
=-0.52155731

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-124.121/93.038
=-1.3340893

Disruptive Pharma AB's return on assets of this year was -0.52155731. Disruptive Pharma AB's return on assets of last year was -1.3340893. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Disruptive Pharma AB's current Net Income (TTM) was -53.13. Disruptive Pharma AB's current Cash Flow from Operations (TTM) was -65.28. ==> -65.28 <= -53.13 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=0/62.3282
=0

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=0/79.6514
=0

Disruptive Pharma AB's gearing of this year was 0. Disruptive Pharma AB's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=39.753/5.687
=6.99015298

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=101.868/21.305
=4.78141281

Disruptive Pharma AB's current ratio of this year was 6.99015298. Disruptive Pharma AB's current ratio of last year was 4.78141281. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Disruptive Pharma AB's number of shares in issue this year was 0. Disruptive Pharma AB's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Disruptive Pharma AB's gross margin of this year was . Disruptive Pharma AB's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=0/101.868
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=0/93.038
=0

Disruptive Pharma AB's asset turnover of this year was 0. Disruptive Pharma AB's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Disruptive Pharma AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.


Disruptive Pharma AB Business Description

Comparable Companies
Address Dag Hammarskjold Road 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score

Get the complete analysis for OSTO:DPHA

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.21
Price